FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166814466> ?p ?o ?g. }

• W3166814466 endingPage "4555" @default.
• W3166814466 startingPage "4555" @default.
• W3166814466 abstract "4555 Background: Inactivation of VHL leads to aberrant stabilization and accumulation of HIF-2α, which drives tumor growth. Patients (pts) with VHL disease are at risk for ccRCC, pancreatic neuroendocrine tumors (pNETs), and hemangioblastomas. Repeated surgeries are often needed to control ccRCC and other VHL disease manifestations. Prior results of this ongoing open-label phase 2 study (NCT03401788) showed activity with belzutifan in VHL disease. Updated results are presented. Methods: Adults with germline VHL alterations, measurable and localized/nonmetastatic ccRCC, no prior systemic anticancer therapy, and ECOG PS 0 or 1 received belzutifan 120 mg once daily until progression, intolerable toxicity, or decision to withdraw. The primary end point is ORR of VHL-associated ccRCC tumors per RECIST v1.1 by independent review committee (IRC). Secondary end points include DOR, time to response (TTR), PFS, and safety. Results: As of June 1, 2020, 61 pts enrolled. Most pts (82%) had ECOG PS 0, and the median number of prior tumor reduction procedures (eg, partial nephrectomy, craniotomy, radiation therapy) per pt was 5 (range, 0-15). Lesions outside the kidney (non-RCC tumors) evaluable by IRC included pNETs (33%) and CNS hemangioblastomas (82%). Median follow-up was 69 wk (range, 18-105), median duration of treatment was 68 wk (range, 8-105), and 56 pts (92%) remain on therapy. There were 22 confirmed responses (ORR, 36% [95% CI, 24-49]) and 7 (11%) unconfirmed responses (documented at 1 time point, to be confirmed at subsequent time point); all were PRs. In pts with confirmed PR, median DOR was not reached (range, 12+ to 62+ wk), median TTR was 31 wk (range, 12-61), and 56 pts (92%) had some reduction in the sum of all target lesion diameters. PFS rate at 52 wk was 98% (95% CI, 89-100). For non-RCC tumors, ORR was 80% (16/20; 1 CR) in pNETs and 32% (16/50; 1 CR) in CNS hemangioblastomas. Of 16 pts with evaluable retinal hemangioblastomas at baseline, 11 (69%) showed improvement per IRC. In those 16 pts, 29 eyes were monitored for retinal hemangioblastomas: 16 eyes (55%) showed improvement, 12 (41%) were stable, and no evaluation was available for 1 eye (3%). All 61 pts (100%) had at least one AE. The most common all-cause AE was anemia (90%), which is considered an on-target toxicity. Treatment-related AEs (TRAE) were reported by 60 pts (98%), and 8 pts (13%) had a grade 3 TRAE. No pts had grade 4/5 TRAEs. One pt discontinued treatment because of a TRAE (grade 1 dizziness). Conclusions: Belzutifan demonstrates clinical benefit and has a favorable safety profile in patients with VHL disease–associated ccRCC, pNETs, and hemangioblastomas. Clinical trial information: NCT03401788." @default.
• W3166814466 created "2021-06-22" @default.
• W3166814466 creator A5004009107 @default.
• W3166814466 creator A5007689146 @default.
• W3166814466 creator A5019280982 @default.
• W3166814466 creator A5022744341 @default.
• W3166814466 creator A5029527227 @default.
• W3166814466 creator A5031748968 @default.
• W3166814466 creator A5034406137 @default.
• W3166814466 creator A5037818785 @default.
• W3166814466 creator A5038623685 @default.
• W3166814466 creator A5038992904 @default.
• W3166814466 creator A5059200225 @default.
• W3166814466 creator A5059690857 @default.
• W3166814466 creator A5066635849 @default.
• W3166814466 creator A5068785092 @default.
• W3166814466 creator A5075863856 @default.
• W3166814466 date "2021-05-20" @default.
• W3166814466 modified "2023-09-23" @default.
• W3166814466 title "Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)." @default.
• W3166814466 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.4555" @default.
• W3166814466 hasPublicationYear "2021" @default.
• W3166814466 type Work @default.
• W3166814466 sameAs 3166814466 @default.
• W3166814466 citedByCount "14" @default.
• W3166814466 countsByYear W31668144662021 @default.
• W3166814466 countsByYear W31668144662022 @default.
• W3166814466 countsByYear W31668144662023 @default.
• W3166814466 crossrefType "journal-article" @default.
• W3166814466 hasAuthorship W3166814466A5004009107 @default.
• W3166814466 hasAuthorship W3166814466A5007689146 @default.
• W3166814466 hasAuthorship W3166814466A5019280982 @default.
• W3166814466 hasAuthorship W3166814466A5022744341 @default.
• W3166814466 hasAuthorship W3166814466A5029527227 @default.
• W3166814466 hasAuthorship W3166814466A5031748968 @default.
• W3166814466 hasAuthorship W3166814466A5034406137 @default.
• W3166814466 hasAuthorship W3166814466A5037818785 @default.
• W3166814466 hasAuthorship W3166814466A5038623685 @default.
• W3166814466 hasAuthorship W3166814466A5038992904 @default.
• W3166814466 hasAuthorship W3166814466A5059200225 @default.
• W3166814466 hasAuthorship W3166814466A5059690857 @default.
• W3166814466 hasAuthorship W3166814466A5066635849 @default.
• W3166814466 hasAuthorship W3166814466A5068785092 @default.
• W3166814466 hasAuthorship W3166814466A5075863856 @default.
• W3166814466 hasConcept C126322002 @default.
• W3166814466 hasConcept C126894567 @default.
• W3166814466 hasConcept C143998085 @default.
• W3166814466 hasConcept C203092338 @default.
• W3166814466 hasConcept C2777472916 @default.
• W3166814466 hasConcept C2778560582 @default.
• W3166814466 hasConcept C2778822529 @default.
• W3166814466 hasConcept C2778886567 @default.
• W3166814466 hasConcept C2779066768 @default.
• W3166814466 hasConcept C2779134260 @default.
• W3166814466 hasConcept C2781278892 @default.
• W3166814466 hasConcept C535046627 @default.
• W3166814466 hasConcept C71924100 @default.
• W3166814466 hasConcept C78795084 @default.
• W3166814466 hasConcept C90924648 @default.
• W3166814466 hasConceptScore W3166814466C126322002 @default.
• W3166814466 hasConceptScore W3166814466C126894567 @default.
• W3166814466 hasConceptScore W3166814466C143998085 @default.
• W3166814466 hasConceptScore W3166814466C203092338 @default.
• W3166814466 hasConceptScore W3166814466C2777472916 @default.
• W3166814466 hasConceptScore W3166814466C2778560582 @default.
• W3166814466 hasConceptScore W3166814466C2778822529 @default.
• W3166814466 hasConceptScore W3166814466C2778886567 @default.
• W3166814466 hasConceptScore W3166814466C2779066768 @default.
• W3166814466 hasConceptScore W3166814466C2779134260 @default.
• W3166814466 hasConceptScore W3166814466C2781278892 @default.
• W3166814466 hasConceptScore W3166814466C535046627 @default.
• W3166814466 hasConceptScore W3166814466C71924100 @default.
• W3166814466 hasConceptScore W3166814466C78795084 @default.
• W3166814466 hasConceptScore W3166814466C90924648 @default.
• W3166814466 hasIssue "15_suppl" @default.
• W3166814466 hasLocation W31668144661 @default.
• W3166814466 hasOpenAccess W3166814466 @default.
• W3166814466 hasPrimaryLocation W31668144661 @default.
• W3166814466 hasRelatedWork W1748266548 @default.
• W3166814466 hasRelatedWork W1983690165 @default.
• W3166814466 hasRelatedWork W2124717287 @default.
• W3166814466 hasRelatedWork W2559803332 @default.
• W3166814466 hasRelatedWork W2615542546 @default.
• W3166814466 hasRelatedWork W2744368889 @default.
• W3166814466 hasRelatedWork W2898370664 @default.
• W3166814466 hasRelatedWork W2920200983 @default.
• W3166814466 hasRelatedWork W2972396084 @default.
• W3166814466 hasRelatedWork W3166814466 @default.
• W3166814466 hasVolume "39" @default.
• W3166814466 isParatext "false" @default.
• W3166814466 isRetracted "false" @default.
• W3166814466 magId "3166814466" @default.
• W3166814466 workType "article" @default.